CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 18.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,102 shares of the company’s stock after purchasing an additional 8,120 shares during the period. Westwood Holdings Group Inc. owned about 0.06% of CRISPR Therapeutics worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Western Pacific Wealth Management LP lifted its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Spire Wealth Management lifted its position in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the period. MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the fourth quarter valued at $80,000. First Horizon Advisors Inc. lifted its position in CRISPR Therapeutics by 33.4% during the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock valued at $80,000 after purchasing an additional 511 shares during the period. Finally, Elkhorn Partners Limited Partnership lifted its position in CRISPR Therapeutics by 22.6% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company’s stock valued at $150,000 after purchasing an additional 700 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 9,973 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. This represents a 5.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares of the company’s stock, valued at approximately $3,288,822.60. This represents a 3.55% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,021 shares of company stock worth $594,771. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Stifel Nicolaus decreased their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Barclays cut their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a report on Friday, May 9th. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $71.75.

CRISPR Therapeutics Trading Up 1.5%

NASDAQ:CRSP opened at $39.25 on Wednesday. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The stock has a 50 day moving average of $37.34 and a two-hundred day moving average of $42.22. The firm has a market cap of $3.39 billion, a P/E ratio of -8.98 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the previous year, the business earned ($1.43) EPS. The business’s revenue was up 71.6% on a year-over-year basis. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.